Lexicon bids farewell to top seller Xermelo in reorganization toward R&D pipeline

Max Gelman

Senior Editor

Three years ago, Lexicon Pharmaceuticals was flying high following the FDA approval and commercial launch of its Xermelo drug, which treats carcinoid syndrome diarrhea …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Lexicon bids farewell to top seller Xermelo in reorganization toward R&D pipeline

Max Gelman

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Trump blog: Judge extends nationwide block on NIH payment cuts

RFK Jr. readies review of childhood vaccine schedule after pledging not to

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Lex­i­con bids farewell to top sell­er Xer­me­lo in re­or­ga­ni­za­tion to­ward R&D pipeline

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Lexicon bids farewell to top seller Xermelo in reorganization toward R&D pipeline